{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:05:31Z","timestamp":1789538731682,"version":"build-2803163510"},"reference-count":44,"publisher":"Societatea Romana de Morfologie","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:p>Background: Parathyroid tumors, mostly single or multiple adenomas, cause a hormonal imbalance via parathormone (PTH) excess, that further increases serum calcium (primary hyperparathyroidism) with both PTH- and calcium-related multi-organ consequences. Testing the bone turnover markers (BTM) profile might capture the essence of associated bone turnover anomalies with practical applications in the clinical setting. Objective: Our objective was to compare the BTM across mineral metabolism panel, glucose profile, as well as circulating irisin levels in patients with primary hyperparathyroidism vs. (tumor-free) controls by refining the analysis based on PTH values quartiles. Patients, Materials and Methods: A prospective study with a single-center design in menopausal adults, who were enrolled between December 2024 and May 2026. Results: 148 enrolled across four PTH quartiles (mean age 63.39 years and menopause length 16.55 years): 27.09\u00b15.56 pg\/mL (Q1), 38.33\u00b12.58 pg\/mL (Q2), 46.34\u00b12.93 pg\/mL (Q3) and 65.78\u00b116.51 pg\/mL in Q4 (p 0.001 for each). Glycated hemoglobin (HbA1c) was lower (statistically significantly): Q4 of 5.74\u00b10.32% compared to non-Q4 of 5.98\u00b10.67% (p=0.006), as well as triglycerides of 103.39\u00b136.34 vs. 124.41\u00b166.26 mg\/dL (p=0.017). Fasting insulin was also different among PTH quartiles, with the highest median value in Q4 of 8.35 (6.47, 11.49) \u03bcIU\/mL (p=0.027). Median homeostatic model assessment for insulin resistance (HOMA-IR) was higher in Q2 vs. Q1 (p=0.034), Q3 vs. Q1 (p=0.016) and Q4 vs. Q1 (p=0.005). Osteocalcin was statistically significantly different among quartiles (p=0.036). Receiver operating characteristic (ROC) curve analysis of osteocalcin to predict primary hyperparathyroidism revealed area under the curve (AUC) 0.645 (p=0.006). The cut-off osteocalcin with the highest Youden index was for the value of 21.26 ng\/mL (sensitivity 63.90%; specificity 63.10%). In Q4, irisin associated a statistically significant and positive correlation with the value of calculated body mass index (BMI) (r=0.361, p=0.042). Conclusions: In this PTH-based quartiles analysis of menopausal females with\/without primary hyperparathyroidism, we found a distinct interpretation of the glucose profile and BTM depending on quartiles, while irisin positive corelated with BMI in cased with parathyroid tumors.<\/jats:p>","DOI":"10.47162\/rjme.67.2.09","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:08:14Z","timestamp":1789495694000},"page":"283-292","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of circulating bone-glucose profile and exerkine irisin across parathormone quartiles in patients with primary hyperparathyroidism"],"prefix":"10.47162","volume":"67","author":[{"name":"Doctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Gheorghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ionovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Occupational Medicine, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana-Claudia","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Costachescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Radiology and Medical Imaging, Dr Carol Davila Central Military Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ciuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Thoracic Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Manda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Research, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Carsote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Doctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; Department of Endocrinology, Carol Davila University of Med","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Kerschan-Schindl K, Gelles K, Butylina M, Crevenna R, Pietschmann P. Bone metabolism in primary hyperparathyroidism. Wien Klin Wochenschr, 2026, 138(7-8):217-224. https:\/\/doi.org\/10.1007\/s00508-025-02670-z","DOI":"10.1007\/s00508-025-02670-z"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Mitrica M, Vasiliu O, Plesa A, Sirbu OM. Multinodular and vacuolating neuronal tumor - challenges and perspectives. Rom J Mil Med, 2025, 128(1):10-16. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.2","DOI":"10.55453\/rjmm.2025.128.1.2"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N. Efficacy of antiresorptive agents bisphosphonates and Denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2023, 14:1098841. https:\/\/doi.org\/10.3389\/fendo.2023.1098841","DOI":"10.3389\/fendo.2023.1098841"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Vasiliu O, Panea CA, Mangalagiu AG, Petrescu BM, C\u00e2ndea CA, Manea MM, Ciobanu AM, S\u00eerbu CA, Mitric\u0103 M. Case management of delirium in patients with major neurocognitive disorders. Rom J Mil Med, 2025, 128(1):67-77. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.9","DOI":"10.55453\/rjmm.2025.128.1.9"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, Zhang M, Guyatt G, Tangamornsuksun W, Zhang Y, Manja V, Bakaa L, Couban RJ, Brandi ML, Clarke B, Khan AA, Mannstadt M, Bilezikian JP. The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. J Bone Miner Res, 2022, 37(11):2351-2372. https:\/\/doi.org\/10.1002\/jbmr.4685","DOI":"10.1002\/jbmr.4685"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Manea MM, Dragos D, Ghenu MI, Enache II, Stoican IC, Ciulavu C, Vasiliu O, Sirbu CA, Tuta S. The neurocardiogenic impact of ischemic stroke: intricacies of cardiac enzymes and the vegetative system. Rom J Mil Med, 2025, 128(1):36-42. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.5","DOI":"10.55453\/rjmm.2025.128.1.5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania AG, Messina C, Napoli N, Mazziotti G. Bone quality in endocrine diseases: determinants and clinical relevance. J Endocrinol Invest, 2023, 46(7):1283-1304. https:\/\/doi.org\/10.1007\/s40618-023-02056-w","DOI":"10.1007\/s40618-023-02056-w"},{"key":"ref7","unstructured":"[8] Carsote M, Paduraru DN, Nica AE, Valea A. Parathyroidectomy: is vitamin D a player for a good outcome? J Med Life, 2016, 9(4):348-352."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Hanly A, Gyftopoulos S, Pelzl CE, He W, Chang CY. Opportunistic screening for osteoporosis: validation study for L1 bone density measurements using contrast-enhanced chest and abdominal CTs. Skeletal Radiol, 2025, 54(9):1887-1895. https:\/\/doi.org\/10.1007\/s00256-025-04892-8","DOI":"10.1007\/s00256-025-04892-8"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Misiorowski W, Czajka-Oraniec I, Kochman M, Zgliczy\u0144ski W, Bilezikian JP. Osteitis fibrosa cystica - a forgotten radiological feature of primary hyperparathyroidism. Endocrine, 2017, 58(2):380-385. https:\/\/doi.org\/10.1007\/s12020-017-1414-2","DOI":"10.1007\/s12020-017-1414-2"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Cuzino D, Capisizu AS. The transformative role of artificial intelligence in the future of radiology. Rom J Mil Med, 2025, 128(6):528-535. https:\/\/doi.org\/10.55453\/rjmm.2025.128.6.6","DOI":"10.55453\/rjmm.2025.128.6.6"},{"key":"ref11","unstructured":"[12] Valea A, Ghervan C, Morar A, Pop DD, Carsote M, Albu SE, Georgescu CE, Chiorean A. Hashimoto's thyroiditis and breast cancer: coincidence or correlation? Arch Balk Med Union, 2016, 51(1):125-128."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Sp\u00e5ngeus A, Bjerner T, Lindblom M, G\u00f6tz C, Hummer A, Salzlechner C, Woisetschl\u00e4ger M. Breaking the silence: AI's contribution to detecting vertebral fractures in opportunistic CT scans in the elderly - a validation study. Arch Osteoporos, 2025, 20(1):42. https:\/\/doi.org\/10.1007\/s11657-025-01524-5","DOI":"10.1007\/s11657-025-01524-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Ro\u015fca AM, Coman SA, Costache DO, Costache AC. The role of ultrasonography. Rom J Mil Med, 2025, 128(2):107-111. https:\/\/doi.org\/10.55453\/rjmm.2025.128.2.3","DOI":"10.55453\/rjmm.2025.128.2.3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Mu\u00f1oz-Torres M, Manzanares C\u00f3rdova R, Garc\u00eda-Mart\u00edn A, Avil\u00e9s-P\u00e9rez MD, Nieto Serrano R, And\u00fajar-Vera F, Garc\u00eda-Fontana B. Usefulness of trabecular bone score (TBS) to identify bone fragility in patients with primary hyperparathyroidism. J Clin Densitom, 2019, 22(2):162-170. https:\/\/doi.org\/10.1016\/j.jocd.2018.06.005","DOI":"10.1016\/j.jocd.2018.06.005"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Bubulac L, Gheorghe IR, Ungureanu E, Bogdan-Andreescu CF, Albu CC, Gheorghe CM, Mu\u015fat O, Eremia IA, Panea CA, Burcea A. Promoting re-epithelialization in diabetic foot wounds using integrative therapeutic approaches. Bioengineering (Basel), 2025, 12(10):1053. https:\/\/doi.org\/10.3390\/bioengineering12101053","DOI":"10.3390\/bioengineering12101053"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP, Caudarella R. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine, 2014, 47(2):435-448. https:\/\/doi.org\/10.1007\/s12020-014-0280-4","DOI":"10.1007\/s12020-014-0280-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int, 2019, 104(3):235-238. https:\/\/doi.org\/10.1007\/s00223-018-00512-x","DOI":"10.1007\/s00223-018-00512-x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2019, 30(1):3-44. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","DOI":"10.1007\/s00198-018-4704-5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Shevroja E, Lamy O, Kohlmeier L, Koromani F, Rivadeneira F, Hans D. Use of trabecular bone score (TBS) as a complementary approach to dual-energy X-ray absorptiometry (DXA) for fracture risk assessment in clinical practice. J Clin Densitom, 2017, 20(3):334-345. https:\/\/doi.org\/10.1016\/j.jocd.2017.06.019","DOI":"10.1016\/j.jocd.2017.06.019"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Langdahl BL, Ralston SH. Diagnosis and management of primary hyperparathyroidism in Europe. QJM, 2012, 105(6):519-525. https:\/\/doi.org\/10.1093\/qjmed\/hcr225","DOI":"10.1093\/qjmed\/hcr225"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Gasser RW. Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy. Wien Med Wochenschr, 2013, 163(17-18):397-402. https:\/\/doi.org\/10.1007\/s10354-013-0235-z","DOI":"10.1007\/s10354-013-0235-z"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Bollerslev J, Cetani F, Gittoes N, Rolighed L. Individualized management of primary hyperparathyroidism. J Intern Med, 2026, 299(6):650-669. https:\/\/doi.org\/10.1111\/joim.70089","DOI":"10.1111\/joim.70089"},{"key":"ref23","unstructured":"[24] Valea A, Carsote M, Moldovan C, Georgescu C. Chronic autoimmune thyroiditis and obesity. Arch Balk Med Union, 2018, 53(1):64-69."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Doshi KB, Chandran M. Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges. Curr Opin Endocrinol Diabetes Obes, 2026, 33(4):131-136. https:\/\/doi.org\/10.1097\/MED.0000000000000965","DOI":"10.1097\/MED.0000000000000965"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Wootton E, De Sousa SMC, Prince RL, McLeod DSA, Pattison DA, Grossmann M. Primary hyperparathyroidism in adults: recent developments in diagnosis and management. Med J Aust, 2026, 224(5):e70194. https:\/\/doi.org\/10.5694\/mja2.70194","DOI":"10.5694\/mja2.70194"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Chiodini I, Gaudio A, Gennari L, Rendina D, Scillitani A, Vescini F, Falchetti A. Endocrine-related osteoporosis: the state of the art. Front Endocrinol (Lausanne), 2026, 17:1797546. https:\/\/doi.org\/10.3389\/fendo.2026.1797546","DOI":"10.3389\/fendo.2026.1797546"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Enache II, Dragos D, Stoican CI, Naum R, Guberna SM, Manea MM. Oxidative stress and nutritional antioxidants in neurological diseases. Rom J Mil Med, 2025, 128(3):215-224. https:\/\/doi.org\/10.55453\/rjmm.2025.128.3.5","DOI":"10.55453\/rjmm.2025.128.3.5"},{"key":"ref28","unstructured":"[29] Nicola Marioara OM, Popescu M, Vl\u0103doianu CN, Carlig V, Carsote M, Ghenea AE. Study of cognitive dyfunctions in thyroid pathology. Curr Health Sci J, 2021, 47(2):256-262. https:\/\/doi.org\/10.12865\/CHSJ.47.02.16"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Bogdan-Andreescu CF, Bubulac L, Albu CC, Sl\u0103vescu DA, B\u0103n\u0103\u0163eanu AM, Botoac\u0103 O, Mu\u015fat GC, Tudor V, Cadar E, P\u0103curar M. Toward smart salivary diagnostics: a comprehensive review of heavy metal biomarkers and digital risk modeling. Diagnostics (Basel), 2026, 16(4):635. https:\/\/doi.org\/10.3390\/diagnostics16040635","DOI":"10.3390\/diagnostics16040635"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Htoo STY, Cusano NE. Management of primary hyperparathyroidism: historical and contemporary perspectives. Endocr Pract, 2025, 31(11):1488-1494. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.009","DOI":"10.1016\/j.eprac.2025.07.009"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Nica S, Sionel R, M\u0103ciuc\u0103 R, Csutak O, Cimponeriu D, Ciobica ML, Nica MI, Chelu I, Radu I, Toma M. Gender-dependent associations between digit ratio and genetic polymorphisms, BMI, and reproductive factors. Rom J Mil Med, 2025, 128(1):78-86. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.10","DOI":"10.55453\/rjmm.2025.128.1.10"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Postole XI, Cimponeriu D, Alexiu-Toma OA, Radu I, Berca L, Eremia IA, Nica S, Nica R. The impact of miRNAs in diabetes mellitus. Rom J Mil Med, 2025, 128(6):508-519. https:\/\/doi.org\/10.55453\/rjmm.2025.128.6.4","DOI":"10.55453\/rjmm.2025.128.6.4"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Sandru F, Dumitrascu MC, Albu SE, Carsote M, Valea A. Hyperpigmentation and ACTH - an overview of literature. Rom Med J, 2019, 66(4):309-312. https:\/\/doi.org\/10.37897\/RMJ.2019.4.2","DOI":"10.37897\/RMJ.2019.4.2"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Roumpou A, Palermo A, Tournis S, Hasenmajer V, Pasieka JL, Kaltsas G, Isidori A, Kassi E. Bone in parathyroid diseases revisited: evidence from epidemiological, surgical and new drug outcomes. Endocr Rev, 2025, 46(4):576-620. https:\/\/doi.org\/10.1210\/endrev\/bnaf010","DOI":"10.1210\/endrev\/bnaf010"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Florescu AG, Pucerea SA, Floria M, Rusu E, Cuiban E, Jinga M, Dragoi Galrinho R, Stanciu SM Targeting heart disease in cardiovascular-kidney-metabolic syndrome: a review of novel therapeutic approaches with prognostic and quality-of-life impact. Rom J Mil Med, 2025, 128(6):554-565. https:\/\/doi.org\/10.55453\/rjmm.2025.128.6.9","DOI":"10.55453\/rjmm.2025.128.6.9"},{"key":"ref36","unstructured":"[37] Dumitrascu T, Preda E, Ionescu M. Emphysematous cystitis: an unreported complication after pancreaticoduodenectomy. Med Surg J (Rev Med Chir Soc Med Nat Iasi), 2015, 119(1):166-169."},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Ijacu AM, Gagiu LG, Staicu IM, Zugravu C, Constantin C. Non-alcoholic steatohepatitis diagnosis and treatment - current concepts. Rom J Mil Med, 2025, 128(1):3-9. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.1","DOI":"10.55453\/rjmm.2025.128.1.1"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Arya AK, Kumari P, Singh P, Bhadada SK. Molecular basis of symptomatic sporadic primary hyperparathyroidism: new frontiers in pathogenesis. Best Pract Res Clin Endocrinol Metab, 2025, 39(2):101985. https:\/\/doi.org\/10.1016\/j.beem.2025.101985","DOI":"10.1016\/j.beem.2025.101985"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Tanase M, Irava BS, Cirstea JO, Samie H. Multiple intestinal neuroendocrine tumors: a literature review and case report. Rom J Mil Med, 2025, 128(4):343-349. https:\/\/doi.org\/10.55453\/rjmm.2025.128.4.9","DOI":"10.55453\/rjmm.2025.128.4.9"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Porr C, Harris DM, Vidrighin A, Catana A, Diaconu C, Preda EM, Popa ML, Berghea EC. Etoricoxib-induced fixed erythema. J Clin Med, 2025, 14(23):8504. https:\/\/doi.org\/10.3390\/jcm14238504","DOI":"10.3390\/jcm14238504"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Sanesi L, Dicarlo M, Pignataro P, Zerlotin R, Pugliese F, Columbu C, Carnevale V, Tunnera S, Scillitani A, Grano M, Colaianni G, Colucci S. Vitamin D increases irisin serum levels and the expression of its precursor in skeletal muscle. Int J Mol Sci, 2023, 24(4):4129. https:\/\/doi.org\/10.3390\/ijms24044129","DOI":"10.3390\/ijms24044129"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Szulc P. Biochemical bone turnover markers in hormonal disorders in adults: a narrative review. J Endocrinol Invest, 2020, 43(10):1409-1427. https:\/\/doi.org\/10.1007\/s40618-020-01269-7","DOI":"10.1007\/s40618-020-01269-7"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Pepe J, Minisola S, Ettorre E, Desideri G, Cipriani C. Cardiovascular involvement in primary hyperparathyroidism. J Clin Endocrinol Metab, 2026, 111(3):603-614. https:\/\/doi.org\/10.1210\/clinem\/dgaf625\"","DOI":"10.1210\/clinem\/dgaf625"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"link":[{"URL":"https:\/\/rjme.ro\/RJME\/resources\/files\/670226283292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:44:20Z","timestamp":1789537460000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/67\/2\/9\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,12]]},"published-print":{"date-parts":[[2026,9,12]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.67.2.09","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}